You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)預計上半年淨虧損擴大至5.63億-6.8億元
格隆匯 05-22 21:32

格隆匯5月22日丨君實生物(01877.HK)發佈公告,公司預計截至2020年6月30日止6個月營業收入4.56億-5.6億元,同比增長47.34%-81.28%;預計期間歸屬於母公司股東的淨虧損5.63億元-6.8億元,上年同期虧損2.9億元;歸屬於母公司股東和扣除非經營性損益的淨虧損5.47億元-6.65億元,上年同期虧損3.08億元。

於作出以上初步預計時,公司亦考慮了公司的實際情況和疫情的影響。2020年上半年公司收入預計較去年同期增幅較大,主要原因為:公司產品特瑞普利單抗於2018年12月正式獲得國家藥品監督管理局有條件批准上市並於2019年2月末起開展銷售,憑藉市場先發優勢、良好的產品臨牀療效、產品價格優勢、經驗豐富的銷售團隊、高效的銷售組織體系建設和符合產品特性的市場推廣方案,預計公司2020年上半年收入較2019年上半年增幅較大。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account